3,991
Views
26
CrossRef citations to date
0
Altmetric
Research Article

Sustained release ivermectin-loaded solid lipid dispersion for subcutaneous delivery: in vitro and in vivo evaluation

, , , , , , , & show all
Pages 622-631 | Received 10 Nov 2016, Accepted 17 Jan 2017, Published online: 10 Mar 2017

Figures & data

Figure 1. X-ray powder diffraction patterns of IVM-SDs, IVM-PMs, IVM, and HCO. IVM-SD, ivermectin-loaded solid dispersion; IVM-PM, physical mixtures of IVM, and HCO; IVM. native ivermectin; HCO, hydrogenated castor oil, the carrier of solid dispersion.

Figure 1. X-ray powder diffraction patterns of IVM-SDs, IVM-PMs, IVM, and HCO. IVM-SD, ivermectin-loaded solid dispersion; IVM-PM, physical mixtures of IVM, and HCO; IVM. native ivermectin; HCO, hydrogenated castor oil, the carrier of solid dispersion.

Figure 2. Fourier-transformed infrared spectroscopy spectra of IVM-SDs, IVM-PMs, IVM, and HCO. IVM-SD, ivermectin-loaded solid dispersion; IVM-PM, physical mixtures of IVM, and HCO; IVM, native ivermectin; HCO, hydrogenated castor oil, the carrier of solid dispersion.

Figure 2. Fourier-transformed infrared spectroscopy spectra of IVM-SDs, IVM-PMs, IVM, and HCO. IVM-SD, ivermectin-loaded solid dispersion; IVM-PM, physical mixtures of IVM, and HCO; IVM, native ivermectin; HCO, hydrogenated castor oil, the carrier of solid dispersion.

Figure 3. In vitro dissolution profile of IVM-SDs, IVM-PMs, and IVM. IVM-SD, ivermectin-loaded solid dispersion; IVM-PM, physical mixtures of IVM, and HCO; IVM, native ivermectin; HCO, hydrogenated castor oil.

Figure 3. In vitro dissolution profile of IVM-SDs, IVM-PMs, and IVM. IVM-SD, ivermectin-loaded solid dispersion; IVM-PM, physical mixtures of IVM, and HCO; IVM, native ivermectin; HCO, hydrogenated castor oil.

Figure 4. Plasma time–concentration profiles of IVM after subcutaneous administration of SD1:3 and IVM in rabbits. The inset figure was the plasma time–concentration profiles after 21 d. The results were expressed as mean ± SD (n = 4). SD1:3, ivermectin-loaded solid dispersion with drug:carrier weight ratios of 1:3; IVM, native ivermectin.

Figure 4. Plasma time–concentration profiles of IVM after subcutaneous administration of SD1:3 and IVM in rabbits. The inset figure was the plasma time–concentration profiles after 21 d. The results were expressed as mean ± SD (n = 4). SD1:3, ivermectin-loaded solid dispersion with drug:carrier weight ratios of 1:3; IVM, native ivermectin.

Table 1. Main pharmacokinetic parameters (mean ± SD, n = 4) of IVM after subcutaneous administration of SD1:3 and IVM in rabbits.

Table 2. Clinical scores of infection of rabbits and number of positive rabbits.

Supplemental material

Table_S2._Regression_coefficient__R2__of_release_profiles.docx

Download MS Word (14.6 KB)

Table_S1.The_Drug_loading_and_encapsulation_rate_of_IVM-SDs.docx

Download MS Word (14.1 KB)

Figure_S2._Cytotoxicity_of__SD13__HCO_and_IVM__on_the_MDCK_cell_lines.jpg

Download JPEG Image (471 KB)

Figure_S2._Cytotoxicity_of__SD13__HCO_and_IVM__on_the_MDCK_cell_lines.docx

Download MS Word (13.4 KB)

Figure_S1._Scanning_electron_microscopy_photomicrographs.jpg

Download JPEG Image (3.6 MB)

Figure_S1._Scanning_electron_microscopy_photomicrographs.docx

Download MS Word (13.7 KB)